TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Dec 31, 2023. Filed Feb 12, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 12, 2024

TEVA$42.97+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of income

(U.S. dollars in millions, except share and per share data)

	Year ended December 31,
	2023	2022	2021
Net revenues	$15,846	$14,925	$15,878
Cost of sales	8,200	7,952	8,284
Gross profit	7,645	6,973	7,594
Research and development expenses, net	953	838	967
Selling and marketing expenses	2,336	2,265	2,429
General and administrative expenses	1,162	1,180	1,099
Intangible assets impairments	350	355	424
Goodwill impairment	700	2,045	—
Other asset impairments, restructuring and other items	718	512	341
Legal settlements and loss contingencies	1,043	2,082	717
Other income	(49)	(107)	(98)
Operating (loss) income	433	(2,197)	1,716
Financial expenses – net	1,057	966	1,058
Income (loss) before income taxes	(624)	(3,163)	658
Income taxes (benefit)	(7)	(643)	211
Share in (profits) losses of associated companies – net	(2)	(21)	(9)
Net income (loss)	(615)	(2,499)	456
Net income (loss) attributable to non-controlling interests	(56)	(53)	39
Net income (loss) attributable to Teva	(559)	(2,446)	417
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$(0.50)	$(2.20)	$0.38
Diluted	$(0.50)	$(2.20)	$0.38
Weighted average number of shares (in millions):
Basic	1,119	1,110	1,102
Diluted	1,119	1,110	1,107

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.